First Patient Enrolled in International Phase III Clinical Trial
We are proud to announce that the first patient has been enrolled in an international Phase III clinical trial investigating a treatment for bacterial vaginosis.
The study will recruit 600 patients across 30 sites in four European countries.
This is a significant milestone in any clinical trial and a testament to the dedication, expertise, and collaboration of everyone involved. We look forward to supporting the successful execution of this important study.
At Aurevia, we work alongside biotech, pharma, medtech, and academic teams to support trials across Europe. Our teams have both deep knowledge and hands-on experience, supporting clinical studies across multiple indications and development phases, often in multinational and multi-site settings.
Curious how we can support your next clinical study? Contact us so we can discuss your needs.
BREAKING